ArticleBMC cancer2007
A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.
Article in BMC cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Recent Advances in Good Manufacturing Practice-Grade Generation of Dendritic Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2020Review
- Closing the system: production of viral antigen-presenting dendritic cells eliciting specific CD8Journal of translational medicine · 2020Article
- Manufacturing Dendritic Cells for Immunotherapy: Monocyte Enrichment.Molecular therapy. Methods & clinical development · 2020Review
- Review
- IL-15 Generates IFN-γ-producing Cells Reciprocally Expressing Lymphoid-Myeloid Markers during Dendritic Cell Differentiation.International journal of biological sciences · 2019Article
- Use of antigen-primed dendritic cells for inducing antitumor immune responsesOncology letters · 2018Article
- Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.BMC immunology · 2017Article
- Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.Cellular immunology · 2015Article
- Dendritic cells derived from pluripotent stem cells: Potential of large scale production.World journal of stem cells · 2014Review
- Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells.PloS one · 2014Article
- Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.BMC immunology · 2013Article
- A novel and simple method for generation of human dendritic cells from unfractionated peripheral blood mononuclear cells within 2 days: its application for induction of HIV-1-reactive CD4(+) T cells in the hu-PBL SCID mice.Frontiers in microbiology · 2013Article
- Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy.Journal of cellular and molecular medicine · 2012Article
- Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.Journal of translational medicine · 2011Article
- Article
- Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation.Journal of translational medicine · 2010Article
- Directing dendritic cell immunotherapy towards successful cancer treatment.Immunotherapy · 2010Review
- Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.Journal of translational medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDendritic cells (DCs) are professional antigen-presenting cells with the ability to induce primary T-cell responses and are commonly produced by culturing monocytes in the presence of IL-4 and GM-CSF for 5-7 days (Standard DC). Recently, Dauer and co-workers presented a modified protocol for differentiation of human monocytes into mature DCs within 48 hours (Fast DC). Here we report a functional comparison of the two strategies for generation of DCs from human monocytes with adaptions for large-scale clinical use.
methodsThe Elutra Cell Selection System was used to isolate monocytes after collection of leukapheresis product. The enriched monocytes were cultured in gas permeable Teflon bags with IL-4 and GM-CSF for 24 hours (Fast DC) or 5 days (Standard DC) to obtain immature DCs. The cells were then transfected with mRNA from the leukemia cell line Jurkat E6 by electroporation and incubated for additional 24 h or 2 days in the presence of pro-inflammatory cytokines (TNFalpha, IL-1beta, IL-6 and PGE2) to obtain mature DCs.
resultsMature Fast DC and Standard DC displayed comparable levels of many markers expressed on DC, including HLA-DR, CD83, CD86, CD208 and CCR7. However, compared to Standard DC, mature Fast DC was CD14high CD209low. Fast DC and Standard DC transfected with Jurkat E6-cell mRNA were equally able to elicit T cell specifically recognizing transfected DCs in vitro. IFNgamma-secreting T cells were observed in both the CD4+ and CD8+ subsets.
conclusionOur results indicate that mature Fast DC are functional antigen presenting cells (APCs) capable of inducing primary T-cell responses, and suggest that these cells may be valuable for generation of anti-tumor vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.